Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
March 14, 2025 16:31 ET
|
Oculis Holding AG
ZUG, Switzerland, March 14, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to annual equity incentive awards granted to members of the executive committee of the Company, as well as...
Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2024 og kynnir áfanga í rekstri félagsins
March 11, 2025 16:30 ET
|
Oculis Holding AG
ZUG, Sviss, March 11, 2025 (GLOBE NEWSWIRE) -- Árið 2024 var árangursríkt og einkenndist af verulegum áföngum þróunarlyfja Oculis á síðari stigum klínískra prófana fyrir meðferð á sjúkdómum í...
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update
March 11, 2025 16:30 ET
|
Oculis Holding AG
ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting...
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update
March 11, 2025 16:30 ET
|
Oculis Holding AG
Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting retina (OCS-01 in diabetic macular edema), neuro-ophthalmic...
Oculis to Present at Upcoming March Investor Conference
March 05, 2025 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
March 03, 2025 03:18 ET
|
Oculis Holding AG
ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
Attachments
...
Oculis greinir frá umframeftirspurn og öðrum niðurstöðum 100 milljón USD útboðs á almennum hlutum
February 13, 2025 19:40 ET
|
Oculis Holding AG
ZUG, Sviss, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), alþjóðlegt líftæknilyfjafyrirtæki með áherslu á nýsköpun til að meðhöndla...
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
February 13, 2025 19:40 ET
|
Oculis Holding AG
ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
February 13, 2025 19:39 ET
|
Oculis Holding AG
ZUG, Switzerland, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
February 07, 2025 18:35 ET
|
Oculis Holding AG
ZUG, Switzerland, Feb. 08, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
...